Chronic Kidney Disease Drug Developers Jockey For Position In Era Of Change
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Upheaval in the chronic kidney disease market ranging from FDA’s ongoing re-evaluation of the safety of erythropoietin stimulating agents to impending major changes in Medicare reimbursement for dialysis patients is resulting in a chain reaction of adjustments in drug development strategies.